GlassScriptPhysician profile
Paul T Dunn
NPI 1386619294
$28,209.54
in general payments reported to CMS, 2019-2025
33 companies · $3,418 in 2025
The $3,418 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,859 · 2020: $1,016 · 2021: $2,808 · 2022: $2,624 · 2023: $8,857 · 2024: $4,628 · 2025: $3,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $4,728 · Travel and Lodging: $619 · Education: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,149.23 |
| Consulting Fee | $4,727.50 |
| Travel and Lodging | $618.66 |
| Education | $407.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,891.86 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $4,094.29 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| E.R. Squibb & Sons, L.L.C. | $3,667.84 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $3,406.16 | 2019-2025 | Siliq, Jublia, Cabtreo |
| Janssen Biotech, INC. | $2,912.84 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,948.76 | 2019-2025 | |
| Lilly USA, LLC | $1,613.71 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $907.18 | 2023-2025 | Zoryve |
| Pfizer INC. | $684.62 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $591.77 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $507.95 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $463.21 | 2019-2025 | |
| Galderma Laboratories, L.P. | $430.51 | 2021-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $400.19 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $367.35 | 2023-2024 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $243.90 | 2019-2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.71 | 2023-2024 | Spevigo, Cyltezo |
| Leo Pharma INC. | $185.09 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $172.84 | 2021-2025 | Opzelura |
| Eli Lilly and Company | $99.00 | 2025 | |
| Celgene Corporation | $61.67 | 2019 | |
| Biowound Solutions, INC. | $56.45 | 2025 | Bio-Connekt |
| Almirall LLC | $49.62 | 2022 | |
| Prugen, INC. Pharmaceuticals | $43.81 | 2019 | |
| Biofrontera INC. | $36.87 | 2019 | |
| Nobelpharma America, LLC | $28.66 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $26.21 | 2019-2022 | |
| Taro Pharmaceuticals USA, INC. | $21.31 | 2019 | |
| Allergan, INC. | $20.01 | 2022 | |
| Kyowa Kirin, INC. | $17.62 | 2024 | Poteligeo |
| Fresenius Kabi USA, LLC | $16.92 | 2023 | |
| Nabriva Therapeutics, Plc | $14.73 | 2022 | |
| Organon LLC | $13.88 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.